Abstract | BACKGROUND: METHODS: A multicenter, randomized, double-blind trial was conducted in patients with documented coronary disease and stable angina to compare a 360 mg dose of diltiazem CD with 100 mg dose of mibefradil. The primary end point was change in time to symptom-limited exercise termination from baseline to 8 weeks. Secondary efficacy parameters included time to onset of persistent ST-segment depression, time to awareness of angina, and change in exercise duration from baseline to 2 and 4 weeks of treatment. RESULTS: A total of 121 patients were randomized to mibefradil and 113 to diltiazem CD. At 8 weeks, the increase in exercise duration was 24.5 seconds greater in the mibefradil group (P =.017; 95% CI 4.4-44.7 seconds). At 8 weeks, time to development of > or =1 mm ST-segment depression was greater by 45.3 seconds (P =.0025; 95% CI 16.2-74.5) with mibefradil, but time to development of angina was not significantly different. CONCLUSION:
|
Authors | Douglas S Lee, Shaun Goodman, Deanne M Dean, Jacques Lenis, Patrick Ma, Pierre B Gervais, Anatoly Langer, PRIDE Investigators |
Journal | American heart journal
(Am Heart J)
Vol. 144
Issue 1
Pg. 60-7
(Jul 2002)
ISSN: 1097-6744 [Electronic] United States |
PMID | 12094189
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Calcium Channel Blockers
- Calcium Channels, L-Type
- Calcium Channels, T-Type
- Mibefradil
- Diltiazem
|
Topics |
- Angina Pectoris
(drug therapy)
- Calcium Channel Blockers
(therapeutic use)
- Calcium Channels, L-Type
- Calcium Channels, T-Type
- Diltiazem
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Mibefradil
(therapeutic use)
- Middle Aged
- Myocardial Ischemia
(drug therapy)
|